Accumulating evidence suggests that disruption of NAV3 contributes progression of breast cancer [32], colorectal cancer [33], T-cell lymphoma [34] and nervous system tumors including neuroblastoma [22]. This evidence concerns the gene NAV3 and colorectal cancer.